{"disease":{"id":"myelodysplastic-syndrome-with-isolated-del-5q","name":"myelodysplastic syndrome with isolated del 5q"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04869683","title":"Biocollection in MyeloDysplastic Syndrome (P-MDS)","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04701229","title":"Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT01869114","title":"Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT02666950","title":"WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Mayo Clinic","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}